Diabetes Industry Veteran Pawel Fludzinski, Ph.D. assumed role of Company President of AmideBio

In News by Admino

BOULDER, CO, September 4, 2018 – AmideBio LLC, a privately held biopharmaceutical company, announced today that Pawel Fludzinski, Ph.D. has assumed the role of Company President in addition to Chief Executive Officer, effective immediately. Dr. Misha Plam is retiring from the role but will remain Chairman of the Board of Directors.

“I am delighted to hand over the full leadership of AmideBio to Dr. Fludzinski,” said Dr. Plam. “Since assuming the CEO role earlier this year, it is clear that he brings all the skills and capabilities needed to lead AmideBio in its development of novel drugs targeting metabolic disease. I look forward to supporting Dr. Fludzinski in my role as Chairman of the Board.”

“I would like to express my gratitude to Dr. Plam for his effort and commitment over the last nine years” said Dr. Fludzinski. “As a result of leadership, the Company is very well positioned to drive forward the development of its glucose responsive insulin analogs and soluble, stable glucagon analogs.”.

About AmideBio:

AmideBio has a pipeline of novel biotherapeutics leveraging its knowhow to drive intelligent design of drug candidates targeting metabolic diseases. Its proprietary Cap-ClipTM technology delivers high-purity and difficult-to-manufacture BioPureTM peptides of any length with unprecedented purity for the pharmaceutical and biotech industry. AmideBio was founded in 2009 by Michael Stowell, Associate Professor of Molecular, Cellular and Developmental Biology at the University of Colorado, Boulder and Misha Plam, a serial entrepreneur.